Translational nephrology: What translational research is and a bird's-eye view on translational research in nephrology

Clinical Kidney Journal

Volumn 8, Issue 1, 2015, Pages 14-22

  Ortiz, Alberto ^a,b  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b Section of Nephrology   (Spain)

Author keywords

acute kidney injury; chronic kidney disease; implementation; registry based clinical trials; review

Indexed keywords

CINACALCET;

ACUTE KIDNEY FAILURE; BASIC RESEARCH; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DISEASE COURSE; HEALTH CARE PLANNING; HEALTH CARE POLICY; HUMAN; INJURY SEVERITY; KIDNEY DISEASE; KIDNEY PRESERVATION; MOLECULAR PATHOLOGY; MORTALITY; NEPHROLOGY; ORGAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REGISTER; RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SOCIOECONOMICS; STUDY DESIGN; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME;

EID: 84928326763     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfu142     Document Type: Review

References (79)

1. Bellomo R, Kellum Ja, Ronco C. Acute Kidney Injury. Lancet 2012; 380: 756-766
2. Remuzzi G, Benigni A, Finkelstein Fo et al. Kidney Failure: Aims For The Next 10 Years And Barriers To Success. Lancet 2013; 382: 353-362
3. Bracey Dw. Acute Renal Failure; Two Cases Treated By Decapsulation And Peritoneal Dialysis. Br J Surg 1951; 38: 482-488
4. Fine J, Seligman A, Frank Ha. Peritoneal Dialysis For Acute Renal Failure. Ny Med 1949; 5: 16-20
5. Lameire Nh, Bagga A, Cruz D et al. Acute Kidney Injury: An Increasing Global Concern. Lancet 2013; 382: 170-179
6. Lozano R, Naghavi M, Foreman K et al. Global And Regional Mortality From 235 Causes Of Death For 20 Age Groups In 1990 And 2010: A Systematic Analysis For The Global Burden Of Disease Study 2010. Lancet 2012; 380: 2095-2128
7. Ortiz A, Covic A, Fliser D et al. Board Of The Eureca-Mworking Group Of Era-Edta. Epidemiology, Contributors To, And Clinical Trials Of Mortality Risk In Chronic Kidney Failure. Lancet 2014; 383: 1831-1843
8. James Mt, Conley J, Tonelli M et al. Meta-Analysis: Antibiotics For Prophylaxis Against Hemodialysis Catheter-Related Infections. Ann Intern Med 2008; 148: 596-605
9. Taguma Y, Kitamoto Y, Futaki G et al. Effect Of Captopril On Heavy Proteinuria In Azotemic Diabetics. N Engl J Med 1985; 313: 1617-1620
10. Fernandez-Fernandez B, Ortiz A, Gomez-Guerrero C et al. Therapeutic Approaches To Diabetic Nephropathy-Beyond The Ras. Nat Rev Nephrol 2014; 10: 325-346
11. United States Renal Data System, 2014 Annual Data Report: Epidemiology Of Kidney Disease In The United States. National Institutes Of Health, National Institute Of Diabetes And Digestive And Kidney Diseases, Bethesda, Md, 2014
12. Era-Edta Registry. Annual Report 2012. http://www.Era-Edtareg.Org/Files/Annualreports/Pdf/Annrep2012.Pdf (Accessed 7 December 2014
13. Genovese G, Friedman Dj, Ross Md et al. Association Of Trypanolytic Apol1 Variants With Kidney Disease In African Americans. Science 2010; 329: 841-845
14. Lipkowitz Ms, Freedman Bi, Langefeld Cd et al. Sk Investigators. Apolipoprotein L1 Gene Variants Associate With Hypertension-Attributed Nephropathy And The Rate Of Kidney Function Decline In African Americans. Kidney Int 2013; 83: 114-120
15. Kidney Disease: Improving Global Outcomes (Kdigo) Glomerulonephritis Work Group. Kdigo Clinical Practice Guideline For Glomerulonephritis. Kidney Int Suppl 2012; 2: 139-274
16. Fornoni A, Sageshima J, Wei C et al. Rituximab Targets Podocytes In Recurrent Focal Segmental Glomerulosclerosis. Sci Transl Med 2011; 3: 85Ra46
17. Mathieson Pw. Proteinuria And Immunity-An Overstated Relationship? N Engl J Med 2008; 359: 2492-2494
18. Queirós Ac, Villamor N, Clot G et al. A B-Cell Epigenetic Signature Defines Three Biologic Subgroups Of Chronic Lymphocytic Leukemia With Clinical Impact. Leukemia 2014. Doi: 10.1038/Leu.2014.252 (Epub Ahead Of Print
19. Spithoven Em, Kramer A, Meijer E et al. Analysis Of Data From The Era-Edta Registry Indicates That Conventional Treatments For Chronic Kidney Disease Do Not Reduce The Need For Renal Replacement Therapy In Autosomal Dominant Polycystic Kidney Disease. Kidney Int 2014; 86: 1244-1252
20. Torres Ve, Abebe Kz, Chapman Ab et al. Angiotensin Blockade In Late Autosomal Dominant Polycystic Kidney Disease. N Engl J Med. 2014; 371: 2267-2276
21. Torres Ve, Chapman Ab, Devuyst O et al. Tolvaptan In Patients With Autosomal Dominant Polycystic Kidney Disease. N Engl J Med 2012; 367: 2407-2418
22. Evenepoel P, Rodriguez M, Ketteler M. Laboratory Abnormalities In Ckd-Mbd: Markers, Predictors, Or Mediators Of Disease Semin Nephrol 2014; 34: 151-163
23. Kidney Disease: Improving Global Outcomes (Kdigo) Ckd-Mbd Work Group. Kdigo Clinical Practice Guideline For The Diagnosis, Evaluation, Prevention, And Treatment Of Chronic Kidney Disease-Mineral And Bone Disorder (Ckd-Mbd). Kidney Int 2009; 76 (Suppl 113): S1-S130
24. Jamal Sa, Vandermeer B, Raggi P et al. Effect Of Calciumbased Versus Non-Calcium-Based Phosphate Binders Onmortality In Patients With Chronic Kidney Disease: An Updated Systematic Reviewandmeta-Analysis. Lancet 2013; 382: 1268-1277
25. Ortiz A, Sanchez-Niño Md. The Demise Of Calcium-Based Phosphate Binders. Lancet 2013; 382: 1232-1234
26. Stone Nj, Robinson J, Lichtenstein Ah et al. 2013 Acc/Aha Guideline On The Treatment Of Blood Cholesterol To Reduce Atherosclerotic Cardiovascular Risk In Adults: A Report Of The American College Of Cardiology/American Heart Association Task Force On Practice Guidelines. J Am Coll Cardiol 2014; 63: 2889-2934
27. Gallegos-Villalobos A, Portolés J, Ortiz A. Application Of The New Cholesterol Guidelines. N Engl J Med 2014; 371: 77-78
28. Tonelli M, Wanner C; Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid Management In Chronic Kidney Disease: Synopsis Of The Kidney Disease: Improving Global Outcomes 2013 Clinical Practice Guideline. Ann Intern Med 2014; 160: 182
29. Kidney Disease: Improving Global Outcomes (Kdigo) Blood Pressure Work Group. Kdigo Clinical Practice Guideline For The Management Of Blood Pressure In Chronic Kidney Disease. Kidney Int Suppl 2012; 2: 337-414
30. James Pa, Oparil S, Carter Bl et al. 2014 Evidence-Based Guideline For The Management Of High Blood Pressure In Adults: Report From The Panel Members Appointed To The Eighth Joint National Committee (Jnc 8). Jama 2014; 311: 507-520
31. http://www.Ema.Europa.Eu/Ema/Index.Jsp?Curl=Pages/Medicines/Human/Medicines/000791/Human-Med-001055.Jsp&Mid= Wc0B01Ac058001D124 (Accessed 7 December 2014
32. Thomas Tc, Rollins Sa, Rother Rp et al. Inhibition Of Complement Activity By Humanized Anti-C5 Antibody And Singlechain Fv. Mol Immunol 1996; 33: 1389-1401
33. De Zeeuw D, Akizawa T, Audhya P et al. Bardoxolone Methyl In Type 2 Diabetes And Stage 4 Chronic Kidney Disease. N Engl J Med 2013; 369: 2492-2503
34. Pfeffer Ma, Burdmann Ea, Chen Cy et al. A Trial Of Darbepoetin Alfa In Type 2 Diabetes And Chronic Kidney Disease. N Engl J Med 2009; 361: 2019-2032
35. Solomon Sd, Uno H, Lewis Ef et al. Erythropoietic Response And Outcomes In Kidney Disease And Type 2 Diabetes. N Engl J Med 2010; 363: 1146-1155
36. Ryan Nj. Ataluren: First Global Approval. Drugs 2014; 74: 1709-1714
37. Welch Em, Barton Er, Zhuo J et al. Ptc124 Targets Genetic Disorders Caused By Nonsense Mutations. Nature 2007; 447: 87-91
38. Torra R, Oliveira Jp, Ortiz A. Uga Hopping: A Sport For Nephrologists Too Nephrol Dial Transplant 2010; 25: 2391-2395
39. Kerem E, Konstan Mw, De Boeck K et al. Ataluren For The Treatment Of Nonsense-Mutation Cystic Fibrosis: A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial. Lancet Respir Med 2014; 2: 539-547
40. Xia Y, Sancho-Martinez I, Nivet E et al. The Generation Of Kidney Organoids By Differentiation Of Human Pluripotent Cells To Ureteric Bud Progenitor-Like Cells. Nat Protoc 2014; 9: 2693-2704
41. Xia Y, Nivet E, Sancho-Martinez I et al. Directed Differentiation Of Human Pluripotent Cells To Ureteric Bud Kidney Progenitorlike Cells. Nat Cell Biol 2013; 15: 1507-1515
42. Martín-Cleary C, Ortiz A. Ckd Hotspots Around The World: Where, Why And What The Lessons Are. A Ckj Review Series. Clin Kidney J 2014; 7: 519-523
43. Wendy E, Hoy We. Kidney Disease In Aboriginal Australians: A Perspective From The Northern Territory. Clin Kidney J 2014; 7: 524-530
44. Garcia-Garcia G, Jha V On Behalf Of The World Kidney Day Steering Committee. Chronic Kidney Disease (Ckd) In Disadvantaged Populations. Clin Kidney J 2015; 8: 3-6
45. Woolf Sh. The Meaning Of Translational Research And Why It Matters. Jama 2008; 299: 211-213
46. Sung Ns, Crowley Wf Jr., Genel M et al. Central Challenges Facing The National Clinical Research Enterprise. Jama 2003; 289: 1278-1287
47. Graham Id, Tetroe J. Nomenclature In Translational Research. Jama 2008; 299: 2148-2150
48. Fiscella K, Bennett Nm, Szilagyi Pg. Nomenclature In Translational Research. Jama 2008; 299: 2148-2149
49. Westfall Jm, Mold J, Fagnan L. Practice-Based Research-'blue Highways' On The Nih Roadmap. Jama 2007; 297: 403-406
50. Trochim W, Kane C, Graham Mj et al. Evaluating Translational Research: A Process Marker Model. Clin Transl Sci 2011; 4: 153-162
51. Butler D. Translational Research: Crossing The Valley Of Death. Nature 2008; 453: 840-842
52. Mischak H, Ioannidis Jp, Argiles A et al. Implementation Of Proteomic Biomarkers: Making It Work. Eur J Clin Invest 2012; 42: 1027-1036
53. Ledford H. Translational Research: 4 Ways To Fix The Clinical Trial. Nature 2011; 477: 526-528
54. Calleros L, Cortés Ma, Luengo A et al. Start-Up Of A Clinical Sample Processing, Storage And Management Platform: Organisation And Development Of The Redinren Biobank. Nefrologia 2012; 32: 28-34
55. Cortés Ma, Irrazábal E, García-Jerez A et al. Impact Of Implementing Iso 9001:2008 Standard On The Spanish Renal Research Network Biobank Sample Transfer Process. Nefrologia 2014; 34: 552-560
56. Siwy J, Schanstra Jp, Argiles A et al. Multicentre Prospective Validation Of A Urinary Peptidome-Based Classifier For The Diagnosis Of Type 2 Diabetic Nephropathy. Nephrol Dial Transplant 2014; 29: 1563-1570
57. Zarjou A, Sanders Pw, Mehta Rl et al. Enabling Innovative Translational Research In Acute Kidney Injury. Clin Transl Sci 2012; 5: 93-101
58. Tuttle Kr, Tuot Ds, Corbett Cl et al. Type 2 Translational Research For Ckd. Clin J Am Soc Nephrol 2013; 8: 1829-1838
59. Martini S, Nair V, Keller Bj et al. European Renal Cdna Bank; C-Probe Cohort; Ckdgen Consortium. Integrative Biology Identifies Shared Transcriptional Networks In Ckd. J Am Soc Nephrol 2014; 25: 2559-2572
60. Ledo N, Ko Ya, Park As et al. Functional Genomic Annotation Of Genetic Risk Loci Highlights Inflammation And Epithelial Biology Networks In Ckd. J Am Soc Nephrol 2014. Pii: Asn.2014010028 (Epub Ahead Of Print
61. He Jc, Chuang Py, Ma'ayan A et al. Systems Biology Of Kidney Diseases. Kidney Int 2012; 81: 22-39
62. Beck Lh Jr., Bonegio Rg, Lambeau G et al. M-Type Phospholipase A2 Receptor As Target Antigen In Idiopathic Membranous Nephropathy. N Engl J Med 2009; 361: 11-21
63. Seitz-Polski B, Payré C, Ambrosetti D et al. Prediction Of Membranous Nephropathy Recurrence After Transplantation By Monitoring Of Anti-Pla2R1 (M-Type Phospholipase A2 Receptor) Autoantibodies: A Case Series Of 15 Patients. Nephrol Dial Transplant 2014; 29: 2334-2342
64. Sanz Ab, Sanchez-Niño Md, Martín-Cleary C et al. Progress In The Development Of Animal Models Of Acute Kidney Injury And Its Impact On Drug Discovery. Expert Opin Drug Discov 2013; 8: 879-895
65. Fresquet M, Jowitt Ta, Gummadova J et al. Identification Of A Major Epitope Recognized By Pla2R Autoantibodies In Primary Membranous Nephropathy. J Am Soc Nephrol 2014. Pii: Asn.2014050502 (Epub Ahead Of Print
66. Kao L, Lam V,Waldman M et al. Identification Of The Immunodominant Epitope Region In Phospholipase A2 Receptor-Mediating Autoantibody Binding In Idiopathic Membranous Nephropathy. J Am Soc Nephrol. 2014. Pii: Asn.2013121315 (Epub Ahead Of Print
67. Janssen Hl, Reesink Hw, Lawitz Ej et al. Treatment Of Hcv Infection By Targeting Microrna. N Engl J Med 2013; 368: 1685-1694
68. Sanchez-Niño Md, Ortiz A. Hcv Infection And Miravirsen. N Engl J Med 2013; 369: 877-878
69. Warnock Dg, Ortiz A, Mauer M et al. Renal Outcomes Of Agalsidase Beta Treatment For Fabry Disease: Role Of Proteinuria And Timing Of Treatment Initiation. Nephrol Dial Transplant 2012; 27: 1042-1049
70. Sanchez-Niño Md, Sanz Ab, Carrasco S et al. Globotriaosylsphingosine Actions On Human Glomerular Podocytes: Implications For Fabry Nephropathy. Nephrol Dial Transplant 2011; 26: 1797-1802
71. Weidemann F, Sanchez-Niño Md, Politei J et al. Fibrosis: A Key Feature Of Fabry Disease With Potential Therapeutic Implications. Orphanet J Rare Dis 2013; 8: 116
72. Pisani A, Sabbatini M, Duro G et al. Antiproteinuric Effect Of Add-On Paricalcitol In Fabry Disease Patients: A Prospective Observational Study. Nephrol Dial Transplant 2014; Doi: 10.1093/Ndt/Gfu273. Epub Ahead Of Print August 20, 2014
73. Antman Em, Harrington Ra. Transforming Clinical Trials In Cardiovascular Disease: Mission Critical For Health And Economic Well-Being. Jama 2012; 308: 1743-1744
74. Strippoli Gf, Craig Jc, Schena Fp. The Number, Quality, And Coverage Of Randomized Controlled Trials In Nephrology. J Am Soc Nephrol 2004; 15: 411-419.
75. Deo A, Schmid Ch, Earley A et al. Loss To Analysis In Randomized Controlled Trials In Ckd. Am J Kidney Dis 2011; 58: 349-355
76. Inrig Jk, Califf Rm, Tasneem A et al. The Landscape Of Clinical Trials In Nephrology: A Systematic Review Of Clinicaltrials.Gov. Am J Kidney Dis 2014; 63: 771-780.
77. Morrish At, Hawley Cm, Johnson Dwet Al. Establishing A Clinical Trials Network In Nephrology: Experience Of The Australasian Kidney Trials Network. Kidney Int 2014; 85: 23-30.
78. Lauer Ms, D'agostino Rb Sr. The Randomized Registry Trial-The Next Disruptive Technology In Clinical Research? N Engl J Med 2013; 369: 1579-1581
79. Lagerqvist B, FröBert O, Olivecrona Gk et al. Outcomes 1 Year After Thrombus Aspiration For Myocardial Infarction. N Engl J Med 2014; 371: 1111-1120